Results 131 to 140 of about 8,187 (229)
Neurolastoma: molecular cytogenetics approach
O neuroblastoma (NB), um tumor solido extracranial derivado de celulas neuroectodermicas da crista neural, e uma das neoplasias infantis mais fascinantes apresentando uma complexa heterogeneidade clinica e biologica.
Yoshimoto, Maisa [UNIFESP]
core
Medullary thyroid carcinoma exclusively associated with a homozygous RET V778I pathogenic variant: a case report with review of literature. [PDF]
Kihara M, Miyauchi A, Akamizu T.
europepmc +1 more source
ABSTRACT Aim To examine the significance of portal vein tumor thrombus (PVTT) as a prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC) treated with chemoradiotherapy (CRT) followed by surgery. Methods The study retrospectively examined 313 patients with borderline resectable (BR) or locally advanced (LA) PDAC who underwent CRT ...
Aoi Hayasaki +9 more
wiley +1 more source
Characteristics and Outcomes of Patients With Dedifferentiated Liposarcoma in a US Community Setting. [PDF]
Butrynski JE +10 more
europepmc +1 more source
ABSTRACT Background Determining whether to resect disappearing liver metastases (DLMs) after chemotherapy for colorectal liver metastases (CRLMs) remains challenging. Methods Patients who underwent hepatectomy after systemic chemotherapy for initially unresectable CRLMs were reviewed. True complete response (CR) was defined as either resected DLMs with
Taihei Soma +9 more
wiley +1 more source
Angiotensin-(1-7) Alleviates Isoproterenol-Induced Cardiac Hypertrophy by Suppressing Autophagy and Apoptosis Through the Synergistic Action of Mas Receptor and Angiotensin II Type 2 Receptor. [PDF]
Wang X +6 more
europepmc +1 more source
The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation
ABSTRACT Allogeneic hematopoietic cell transplantation (allo‐HCT) is an effective treatment for patients with high‐risk hematologic malignancies. Over the last decade, gut microbiota composition during allo‐HCT has been associated with patients' outcomes.
Wenjing Hao +4 more
wiley +1 more source
NX-1607: lifting the Cbl-b brake to promote T cell activation through MAPK/ERK pathways. [PDF]
To A, Sugimura R.
europepmc +1 more source
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez +17 more
wiley +1 more source

